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Cynomolgus monkeys (Macacafascicularis) are members of the macaque
species, and represent a non-human primate that is phylogenetically similar to man.
Because of this, macaques provide an excellent animal model for preclinical
pharmaceutical trials, as well as the study of a variety ofhuman diseases, most notably,
acquired immunodeficiency syndrome (AIDS) and lymphomagenesis. Similarities
include the organization ofboth their immune and hematopoietic systems, including
specific cellular antigens. As a result, this similarity in cellular markers has provided an
invaluable research template for a number of immunophenotyping techniques. Much of
this research has been directed towards 1) identifi.cation of similar, biologically important
cellular markers and cytokines among animal species 2) development and standardization
of techniques that allow reproducible identification of these molecules, and 3)
applications of these techniques in the study ofhuman disease processes.
INTRODUCTION TO Th1MUNOPlIENO'rYPING
Immunophenotyping involves the use of monoclonal antibodies (mAb),
specifically designed to recognize and bind to unique, cellular antigens. Antigens may be
cell-surface oriented, or located in the cytoplasm or nucleus, The mAb's are labeled with
a chromophore prior to or after binding the targeted cellular antigen. Chromophores
include fluorescent, enzymatic, or radioactive substances, allowing identification of
targeted cell types. In this way, specific cell types may be isolated and quantified.
Currently, a number of different technologic tools and methods for immunophenotyping
are available, including the use offlow cytometry.
INTRODUCTION TO FLUORESCENT CYTOMETRY
Flow cytometry combines cell-sorting technology with fluorescent
immunophenotyping and represents a powerful tool for the rapid identification and
quantification of cells in heterogeneous populations. One clinical application offlow
cytometry in human medicine is the isolation and quantification of leukocytes,
specifically, lymphocytes and lymphocyte subtypes in whole blood, using combinations,
or "panels" of chromophore-bound anti-human mAb's. Initial or sequential results allow
quantification and identification of shifts in blood lymphocyte populations, which reflect
alterations in the immune response. Current applications of this technology in human
medicine include use as a prognostic indicator for patients infected with human
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immunodeficiency virus (lllV) and identification and differentiation ofdifferent T- and
B-ceU leukemias and lymphomas.
STUDY OBJECTIVES
Duplication or reproduction of a standardized human panel in cynomolgus
monkeys would provide a useful tool for preclinical efficacy and toxicologic evaluation
of potential therapeutics for human diseases in an animal model. Cynomolgus monkeys
are less aggressive and more manageable than other macaques. They are also cost-
effective, and represent a more readily available source of animal subjects for many
pharmaceutical developers. Currently, there are very few specific reagents available for
the immunophenotyping of monkey leukocytes. Initial goals of this project included 1)
identification ofcommercially available human mAb's that would cross-react with
Cynomolgus leukocyte antigens, and 2) duplication or development of a standardized
procedure and panel of mAb' s that could be used to classify and quantify lymphocyte
subpopulations using flow cytometry on Cynomolgus whole blood samples. A review of
the available literature revealed several other studies with similar goals. Cross-reactivity
trials of several mAb clones were necessary, and, in some instances, the primary focus in
many of these studies.
Interestingly, no specific information regarding details of the actual operation of
the flow cytometric technology was provided in any of this research. During this project,
it became clear that the technical operation of this equipment required much
experimentation and research regarding appropriate use. Because appropriately
established parameters would provide the foundation by which results were generated,
detailed information regarding flow cytometric techniques used for this project are





The idea of using chemically labeled antibodies as reagents for the detection of
cellular antigens dates back nearly 60 years. In the last 20 years, with the broadening of
our knowledge base and the availability of improved high technologic equipment, there
has been an explosion of knowledge regarding the identification of these cellular
markers. This includes the elucidation not only of the presence and location of these
antigens, but the structure and function as well. Central to this rapidly expanding
knowledge base are cellular-signaling, and the resultant biologic response of cells to
these signals.
Cellular antigens often represent cellular receptors, which, once activated by
binding a specific ligand, may generate a cascade of cellular events that may have either
local, or global impact on the entire organism. Normal cellular responses, as well as
abnormal, have been the subject of much study. The diversity ofbiologic responses is
extraordinary, ranging from the normal death of a single cell, to abnormal cellular
proliferation resulting in cancer. Hundreds of cellular markers have been identified and
studied, and many of these markers and their biologic properties, have been found to be
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conserved among species. Conservation of these molecules among species allow: animal
resources to be used for continued research in the areas of cellular metabolism and
responses. These include the elucidation of the- roles of cytokines, cellular genetics
cellular activation, differentiation, proliferation and death and regulation of the immune
response.
Flow cytometry was originally developed to provide a rapid, sensitive,
quantitative means ofanalyzing a particular cell population in a heterogeneous cell
mixture. Previously, quantitative immunophenotyping was limited to traditional
microscopic methods, which proved both time-consuming and subjective. The impact of
the mv/AIDS pandemic likely exerted the strongest influence on the technologic
evolution offlow cytometry over the last 15 years [7]. Although experimental and clinical
applications of this technology have become more diversified, research and clinical







INSTRUMENTATION AND METHODOLOGY BASICS
Flow cytometers can generate infonnation regarding physical, biochemical, and
antigenic properties of single living (or dead) cells. In general, the instrumentation
requires that cell preparations be suspended in a liquid medium, or "sheath" fluid. When
the prepared sample is introduced into the machine, the suspension is channeled into
,
increasingly thinner columns, ultimately separating individual cells in a linear fashion.
Individual cells are then directed past excitation laser beams, resulting in the emission of
photons. Two distinct analytic measurements may be made~ the angle at which the
photons scatter, and their wavelength. Two parameters, designated as Forward Angle
Scatter (FSC), and Side (or Orthogonal) Angle Scatter (SSC), represent the measured
angle of the scattering ofvisible light (460 om), and can be related to specific physical
properties of the cell.
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LIGH S ATIERING
FSC distinguishes differences in cell size while repre nt cell compi xity
(mononuclear, lobularity, and granulation). The multiangle polariz d scatter allow not
only cell quantification, but cell sorting as well. Depending onthe softwar u ed
different cell types can be graphically displayed and viewed as di tinct cell populations.
Figure 1 provides a graphical scatterplot representation ofthe' distinction 0 blood
leukocyte populations using these parameters. ,I
A.
• B.• c.
FiglU'e 1. Graphical representation of a typical
light scatter dot-plot depicting separation of distinct
leukocyte populations in appropriately prepared
whole blood. FSe separation is based on increa lng
cell size, while sse separation is based on cell
complexity. A = Cellular debri and platelet .B =
Lymphocytes.C = Monocytes. 0 = Granulocytes.
Forward Scatter (FSC)
Cellular debris and platelets are small, without much complexity, and so reflect
very low FSC and SSC properties. Lymphocytes are small, mononuclear cells, reflected
by low FSC and SSC properties. Granulocytes are larger cells, reflected by increased
FSC. Segmented nuclei and presence of granules translates into a very high SSC signal.
Monocytes are large cells, emitting a high FSC signal, with intennediate nuclear and
cytoplasmic complexity, resulting in an intennediate SSC signal.
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FLUORESCENT SCATTERING
Flow cytometers also employ additional excitation sources that operate at a
1
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single- or narrow-band wavelength, restricting photon emissions to those ofa similar
wavelength. These lasers are d.esigned to generate photons from fluorescent
chromophores, which may be conjugated to mAb's (fluorescent probes), and can be
bound to cells. (i.e., "stained" cells). A few examples ofcommonly used fluorescent
probes include mAb-bound peridinin chlorophyll A protein (PerCP), fluorescein
isothyocyanate (FITC), and R-phycoerythrin (PE), which emit photons ofwavelengths of
670 om, 530 om, and 575 om, respectively. These probes can be used alone, or in
combination to analyze unique antigenic determinants on or within individual cells,
delineating different cell populations.
Because the fluorescent wavelengths relate to colors of the spectrum, different
chromophores are often referred to in terms of a specific color (FITC = green, PE= red,
etc.) When more than one probe is utilized on a single cell preparation (i.e., two-, three-
and four-color flow), the chromophores are segregated as numerical parameters, such as
Fluorescent 1 (FLI), Fluorescent 2 (FL2), etc. Figure 2 depicts an example of the





Figure 2. Graphical repre nt tion of typical two-
color fluorescent labeling depicting sellaration of cell
population bll cd on anti enic properties. Two
unique antigens are de cribed CDIl IlDd Db.
These are targeted by cbromopbore labeled
monoclonal llDtibodies (mAbs) !Illeeific for each
antigen as indicated. A intensity of FITC or PE
fluore cenee increases, clouds move farther along the
x or y-axis. r peeth'ely. Ullper left qUlldrllDt: Cell!l
e pressing CDa only. Lower left quadrant: No
e presion of either antigen (unstained or negati.ve
cell population). Lower right quadrant: Cell
e pressing CDb onI}'. Upper right quadrant: Cell!l
eJ.preS!lin~ both antigens CDa and CDb.
Currently, a vast array of unconjugated chromophores, unconjugated speci.e -
specific rnAb's, as well as conjugated probes, are commercially available. Which prob
are chosen depends on the animal species used for the study, known cellular antigens of
the cell population of interest, and the experiment or protocol design. Flow cytometric
immunophenotyping involves two important parameters, which can be distinctly
measured: the wavelength emitted, and the intensity ofth emission. If antigens are
unique to a cell type, these cells, when stained, are easily identified by th wav length of
the photons emitted. However, because some antigens are shared among diffi rent cell
types, evaluation of wavelength alone would be unreliable as a means fidentification
when a heterogeneous sample, containing cell types that cross-react with certain mAb's
is evaluated.
Fluorescent intensity is directly related to the concentration of cellular antigen
expressed. Because of this, if the level of antigenic expression is known among the cell
types under investigation, the degree of intensity can be used to resolve cross-reacting
cell populations. In this way, cell types may be sorted not only on the basis of the
fluorescent wavelength emitted by cells bound to probes, but by their staining intensity as
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well. It is this concept that allows a commonly used Feagent-pair CD45/CDI ) to be
utilized for the resolution ofoverlapping cell populations which will be di cu ed in
greater detail later. . t
GATING CONCEPTS
Evaluation and manipulation of the data generated by the above-mentioned
parameters is performed using cytometric software. Cytometric software varies from
instrument to instrument, but all software can display data in numerical, as well as
graphical form. Software is typically designed for specific applications, with a number of
different protocols for their utilization.
For this project, the Becton-Dickinson FACSCalibur Instrument, and CELLQuest
software was used. This software is well suited for the sorting and evaluation of the
heterogeneous leukocyte populations found in whole blood. With CELLQuest, individual
cells, or "events" can be visualized using histograms, contour plots, and scattergrams.
Because scattergrams have traditionally been used in the evaluation of peripheral blood
leukocytes, this graphical representation was chosen for this project. The scattergrams,
or "dot-plots" include an x- and y-axis, which can be defined by the operator as a
function of the measurable parameters of light-scatter (FSC, SSC), and fluorescent scatter
(FL1, FL2, etc.), in either linear or logorhythmic scale. All events displayed can be
analyzed and numerically quantified based on the parameters chosen. Further, graphical
events can be isolated, by confining them to a "region" (Rl), or quadrants, which can be
defined (or drawn) directly on the graph by the operator. Similarly, all events in regions
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or quadrants can be numerically quantified. A second graph may then be construc ed
this time using different parameters, and fonnatted to display only the events that were
contained within RI, a procedure known as "gating". The operator may define the gate
corresponding to RI in any way. For simplicity, gates are often defined using the same
enumeration as the region it is related to. Thus, the gate corresponding to Rl may be
defined as G 1. Multiple regions may be drawn, and multiple gates chosen for display on a
single graph. In this way, events isolated by light scatter properties, may be viewed
through a gate that was defined using fluorescent scatter, and vice versa This procedure
is known as fluorescent gating, or ''backgating''. Gating allows the visualization of only
events that meet the criteria ofall operator-chosen parameters. This sequential process
allows the operator to isolate, purify, and enumerate a targeted cell population, based on
the successive confinement of events by the parameters chosen for each graph.
OPTIMIZATION TECHNIQUES
Operation of flow cytometers requires a certain skill level involving the
instrument controls, software, and known parameter properties of specific cell
populations. Calibration techniques are varied, specific for the instrument used, and
generally straightforward. Instrument optimization techniques, however, are more
complex, and require some knowledge of the signal processing incorporated by flow
cytometers. Photomultiplier tubes (PMTs) and photodiodes are two types of photon
detectors utilized by flow cytometers. Photodiodes are less sensitive to light, and are
used to detect only strong light signals, such as FSC. Signals emitted for any of the
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measurable parameters may be individually diminished or increased by adjustin 'Specific
amplifier gain controls. PMTs are used to detect the weaker signals emitted by sse, and
FL. In addition to amp gain, the voltage ofPMTs may also be adjusted, or "multiplied"
resulting in changes in signal strength. Thus, voltage adjustment result in large changes
in signal strength, while adjustments of amperage gain allows "fine-tuning", or
'lweaking" of the signal.
When evaluating samples using flow cytometry, it is important to include as much
ofthe cell population of interest as is possible. This requires that the operator be able to
recognize and distinguish events that represent known cell population distributions, from
events that are secondary to debris (cell fragments) and platelets. FSe and sse may be
adjusted to minimize debris, and maximize cell populations of interest. An example of
how cell populations may be adjusted using these parameters is provided in Figure 3. A
limiting threshold level may also be set to exclude undesired noncellular events along the
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Figure 3. Optimization of FSC and SSC amperage gain and SSC voltage controls allow8
distinction of ceO populations and detection of most cellular events. Additional adjustment of
FSC limiting threshold allows exclusion of noncellular events, and is represented by the
dotted line on the second dot plot above. All events to the left of this line are excluded.
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Other instrument adjustments are concerned with fluorescent optimization.
Adjustments are necessary to minimize interfering fluorescence secondary to non-
specific mAb binding, and autofluorescence. Isotypes ofimmunoglobulin G (IgO) are
most commonly used to manufacture mAbs. Individual immunoglobulin molecules
contain two potentially reactive moieties, the Fc and FAb regions. It is the FAb region of
mAbs that is engineered to recognize, and bind to, specific epitopes ofinterest. Howeyer
many cell types express receptors that non-specifically bind the Fc region of IgG
antibodies. In addition, some non-stained (or "negative") cells may emit varying
intensities of inherent autofluorescence. These non-specific sources offluorescence,
termed ''background fluorescence" can, and often de, interfere with measurements of
fluorescence emitted by stained cell populations of interest. Therefore, the use of
properly designed negative controls is critical.
Negative controls should be engineered from the same antibodies as the probes, but
without FAb specificity for the antigens being analyzed. Using antibody isotypes similar
to the probes, but specific for a different species often attains this goal. They should be
labeled with the same fluorescent chromophores as will be used on the sample under
investigation. Thus, when negative controls are added to a sample of unstained cells (i.e.,
not bound to specific probes), only background fluorescence will be emitted. Both
fluorescence and autofluorescence, emitted respectively by non-specific binding of
negative controls and non-staining cells in the sample, can be reduced by adjusting the
voltage and amperage ofthe photomultiplier detector (s) for each fluorescent wavelength
(optimization of fluorescence). For two-color flow cytometry, using CELLQuest
14
software, this is performed by shifting the events that represent background fluorescence
into an operator-defined LL quadrant on aFLl/FL2 scattergram igure 4).











0 Fl1 1000 Fl1
Figure 4.0ptimization of fluorescence. Either an unstained cell sample and/or an I G i type
control may be used to minimize autofluorescence and non-specific fluorescence (together termed
"background" fluorescence), respectively. These nonspecific events are shifted to the lower left
quadrant on a fluorescent plot by adjusting FLl and FL2 amperage and voltage.
When using multiple chromophores in a single sample preparation, the most
important adjustment involves optimization of fluorescent compensation. Often,
fluorescent emissions from different chromophores may overlap spectrally. This is
especially evident when a single excitation beam is used to excite different
chromophores. Expanding the number of excitation lasers allows a better physical and
kinetic separation between signals, but many of the cytometers currently available are not
this well-equipped due to the expense of additional lasers.
Fortunately, current technology provides a means to compensate for this spectral
overlap. Electronic compensation requires single stained samples, each containing a
single fluorescent probe. Alternatively, a singl.e sample, combining all probes to be
utilized, can be used, provided that it contains cells that uniquely bind only one type of
probe. When multiple probes are used in a single sample, compensation voltages are
adjusted by subtracting the signal of chromophore A that is measured as a function of
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chromophore B, from the signal emitted by chromophore B, and vice versa. CELLQuest
software provides specific voltage controls, tenned FLI-%FL2 (where spectral overlap of
chromophore 2 is removed from the signal emitted by chromophore I), and FL2-% FLI
(where spectral overlap of chromophore 1 is removed from the signal emitted by
chromophore 2), which may be set while viewing a FL11 FL2 scatterplot divided into
user-defined quadrants. In this way, compensation is established by lining up the mean





Figure 5. Optimization of fluorescent compensation. Compensation voltages are adjusted to
reduce spectral overlap between cbromophores. The mean of FLl and FL2 are shifted to
line up witb tbe mean of tbe nonspecific events ("unstained" eventll).
Although more involved, a similar process is used for compensation optimization
when using three- or four-color flow. Again, procedures regarding all optimization




Tenninology of cellular antigens is, at best, confusing. This may be a reflection
of the rapidity at which the same antigens have been discovered and named by different
researchers. As a result, several notations may reference one cellular antigen. Recent
attempts to establish a universal reference system have resulted in the "CD" numbering
system.
Specific antigens are labeled as numerical CD or "clusters of differentiation"~
this notation will be used here. A number ofunique lymphoid cell-surface markers have
been identified, and are commonly utilized to target and quantify specific lymphocytes in
flow imrnunophenotyping. These include CD3, specific for all T lymphocytes (except
Natural Killer cells), CD20, specific for B-Iymphocytes, and CD56 and CD16, specific
for Natural Killer (NK) cells. T-cell subtypes can further be classified as T-helper
lymphocytes (Th) which express CD3, and CD4, but are CD8 negative (CD3+, CD4+,
CD8-), and cytotoxic T-Iymphocytes (CTL), which express CD3 and CD8, but are CD4
negative (CD3+, CD8+, CD4-).
The availability of mAbs that specifically bind these unique antigens has allowed
lymphocyte sub-typing and quantification using flow cytometry. Proper flow cytometric
analysis oflymphoid cells in whole blood requires that the lymphoid population be
isolated from other cell types, which can be established by defining a "lymphocyte gate".
The National Committee for Clinical Laboratory Standards (NCCLS) has described
certain guidelines regarding quality assurance for flow cytometric lymphocyte
immunophenotyping, which include minimal requirements for gate "purity" and
17
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"recovery" when establishing optimal lymphocyte gates. Gate purity refers to the
percentage oflymphocytes within the defined lymphocyte light-scattergate (FSCI SSC),
relative to all other non-lymphoid events within the same gate. Recovery refers to the
percentage of lymphocytes within the light-scattergate relative to the total number of
lymphoid events recorded in the original sample acquisition. Depending of the reference,
purity and recovery are recommended to optimized to at least > 80%, and > 90%,
respectively [3,5,8,16).
One commonly used protocol for performing lymphocyte analysis on peripheral
whole blood includes the use of a CD45/CD 14 reagent pair. The protocol allows the
establishment of an optimal lymphocyte gate by adjusting gate characteristics of purity
and recovery as a quality control measure.
ESTABLISIllNG THE LYMPHOCYTE GATE USING CD45 AND CD14 ANTIGENS
For two-color flow immunophenotyping of peripheral blood lymphocyte analysis,
it is necessary to aliquot the specimen into several sample tubes, each containing
combinations of two-color mAb reagents; the paired reagents are collectively referred to
as a "panel". Most commonly used panels consists of six two-color reagent pairs,
exploiting the specific lymphocyte antigens previously mentioned, as well as two
additional antigens, CD45 and CDI4, and a negative control. Figure 6 shows the typical
probe pairs used.
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Tubel: Negative isotype controls FITC-IgG / PE-IgG
Tube 2: Unstained sample
Tube 3: FITC-CD45/ PE CDl4
Tube 4: FITC-CD43 / PE CD4
Tube 5: FITC-e03 / PE C08
Tube 5: mC-CD3 / PE CD20
Tube 7: mC-CD3 / PE COl6 and PE-CD56
Figure 6. Typical monoclonal antibody probe pairs used for lymphocyte immuDopbenotyping.
The IgG FITCngG PE paired sample is used for optimization procedures, and to
define the negative population, as previously described. The CD45 FITC/CD14 PE
reagent pair is used to establish the optirnallymphocyte gate while maintaining quality
control. CD45 is a pan.-Ieukocyte cell-surface antigen that is present on granulocytes,
monocytes, and lymphocytes. However, each cell type expresses it in different
concentrations. Because of this, probes using CD45 mAbs may be used to distinguish
leukocyte populations based on their different staining intensities.
Cells exhibiting increasing numbers of cell surface CD45 antigen will stain with
increasing fluorescent intensities. Granulocytes stain the weakest (dim), lymphocytes
stain the brightest (bright), and monocytes exhibit intermediate staining intensity. This
single parameter is insufficient to distinguish these cell populations, however, because
significant overlap exists in the intensity distributions. This overlap may be resolved
with the use of CD 14. CD 14 is expressed in high levels on monocytes, and dimly on
mature neutrophils. By combining CD45 and CDI4, it is possible to differentiate these
cell populations based on their immunofluorescence, using two different chromophores,
while viewed on a FL1/FL2 scattergram using this reagent combination allows the
operator to define a lymphocyte gate, via backgating.
-
This backgating process is depicted in a step-wise fashion in Figures, 7a-f. A
sample stained with CD45 FITC/CD14 PE is first displayed on an ungated FLlfFL2 dot
plot. FL1 is typically defined on the x-axis, representing increasing intensity ofFITC
staining by cells. FL2 is defined on the y-axis, representing increasing intensity of PE
staining of cells. Although all leukocytes stain with CD45 FITC, the monocytes will also
be stained with CDl4 PE (CD45+ and
CD14+), allowing visualization of three
distinct cell populations, and an area that
represents the negative population. Regions are
then defined by the operator, segregating these
populations (Figure 7a). The region (R1) that
is defined for the lymphocyte population
(bright CD45+, CD14-) must be large enough
to include all the lymphocytes in the sample,
i.e., the total number oflymphocytes. Defining




Figure 7a. Defining regions that isolate
differeDt leukocyte populations based
on antigenic properties of light scatter
using CD43 and CD14
the lymphocyte population by including CD45+/CD14- monocytes, and possibly some
CD45+ granulocytes. A smaller region, although representative of a more pure
lymphocyte population, is likely to exclude some lymphoid events, reducing lymphocyte
recovery. It is clear that there exists an indirect relationship between purity and
recovery, The events in Rl are then displayed on a light-scatter (FSC/SSC) plot, which is
gated on Rl. A new region (R5) is drawn to include only the cells with low sse, which
21l
represent lymphocytes (Figure 7b). The exclu ion
of the high SSC cells, which represent monocyte
and granulocyte contamination within Rl, further
purifies the lymphocyte population. It is, in fact
these CD45 bright and low FSC properties that
define the lymphocyte population. The light-
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gate. All events measured in the sample are
now displayed (Figure 7c). The events within R5
Figure 7b. Define R5 on light scatter
plot adjusted to display only events
contained within R1
are then backgated to the original regions drawn on the FLIfFL2 scatter plot, this time
gated on R5 (Figure 7d). The events that now fall within the Rl region should represent a
~---------'!"'"."-..," UNGATED
o
Figure 7c. Remove gate to display all





Figure 7d Backgated to display only
events of R5 region on fluorescent dot
plot.
pure lymphocyte population. The R5 region drawn on the light scatter plot represents the
lymphocyte gate, and can be optimized to fulfill .eeLS guidelines ofrecovery and
purity.
Percent (%) Lymphocyte Recovery is defined as the number (# )oflymphocytes in
the light scattergate, divided by the total number oflymphocytes in the sample, and
multiplied by 100. This may be calculated by dividing the number of events backgated
from R5 (light-scatter, ungated) and displayed in the Rl region of the fluorescent scatter
plot (gated on R5), by the number of events confined to the R5 region drawn on the light-
scatter gate (gated on R1).
Percent (%) Lymphocyte Purity is defined as the number (#) oflymphocytes in the
light scattergate, divided by the # of events in the light scattergate, and multiplied by 100.
This may be calculated by dividing the number ofevents backgated from R5 (light-
scatter, ungated) and displayed in the Rl region of the fluorescent scatter plot (gated on
R5), by the number of events in the R5 region of the light-scatter gate (ungated).
Optimization of the lymphocyte gate is
performed by defining a new region (R6) on the
same light-scatter plot, and reformatting the
graphs appropriately, so that R6 data replaces R5
data (Figure 7e). Using the above calculations on
the data collected, R6 is adjusted until the
criteria for recovery and purity is attained,
establishing the lymphocyte gate. Data is then








Figure 7e. Create and adjust R6 for
optimization of purity a.nd recovery.
fluorescent scatter plot, which is formatted to display only ev nts contained within th
[mal R6 region of the light scatter plot. (Figure 7f). All remaining paired sample are
evaluated using this established gate and all data collected and instrument settings may be




Figure 7f. Calculations for purity and
recovery utilize data collected from
Ouorescent scatterplot gated to display





REVIEW OF THE LITERATURE
Early attempts at subtyping cynomolgus, as well as other non-human primate
lymphocytes, included delineation ofbasic Band T subtypes using techniques established
in humans with anti-human monocolonal antibody reagents. These included spontaneous
rosetting ofT lymphocytes with sheep erythrocytes (where the erythrocyte receptor was
antigenic detenninant TIl, a CD2 epitope), and alpha-naphthyl-acetate esterase (ANAE)
staining [11,12) Separation of cell lines using these techniques was subjective, as
distinction of T and B subtypes was based on staining intensities assessed via light
microscopy. Because no specific anti-monkey MAbs were available, much research
regarding lymphocyte subsetting in cynomolgus monkeys has included cross-reactivity
trials.
The earliest attempts to delineate cynomolgus peripheral blood lymphocytes using
flow cytometry focused primarily on cross-reactivity trials with available anti-human
MAbs [6]. One color flow was used to evaluate several FITC labeled anti-human CD2
(TI I, TI2), CD4 (T4, T4a) and CD8 (T8, T5, T8b, T8c) clones. 37 non-human primates,
induding 7 adult cynomolgus monkeys were utilized, and results were pooled. Blood
leukocyte isolation was performed using the Ficoll-Hypaque density gradient. The
method for delineating cell populations is described as "cytofluorographic analysis of cell
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populations was performed on a fluorescent-activated cell sort r -I, B cton-
Dickinson, Mountainview, CA). This early attempt did not utilize any pecific
lymphocyte gating technique, and data was expressed as the p reent ofpo itively :taining
cells. Cross reactivity was noted in several of the mAb clones used, resulting in the
conclusion that these findings "support the notion that the degree of sharing of T-0 II
specific surface antigens between man and other primate species reflects the phylogenetic
distance between them. Moreover, they raise provocative issues concerning the potential
uses ofmAbs in elucidating both structural and functional roles of these T cell-specific
structures"
In 1990, Sagara, et al, compared the rapidity and precision of the ANAE technique
to that of one-color flow cytometry [lOJ. An anti-human TIl mAb (CD2 antigenic
determinant) was used as a pan-T cell marker, and goat-anti-monkey IgG was used to
target B cells; FITC was used to label all antibodies. Isolation of blood leukocytes was
performed using a Percoll density gradient, and lymphocyte subtyping wa based on
enumeration of mononuclear cells that reacted with each antibody. One again, a sp cific
lymphocyte gating technique is not described. In this study, the correlation coefficient (r)
revealed flow cytometry to be more precise, as well as advantageously more rapid than
the ANAE immunophenotyping technique.
In 1993, Bleavins, et aI, used one color flow to assess cynomolgus peripheral blood
lymphocyte populations in whole blood, using a lysing agent (ammonium chloride),
rather than a density gradient technique [2]. PE labeled anti-human clones for CD4 (anti-
leu 3a), CD8 (anti-leu 2a, and CD20 (anti-leu 16) were assessed. Values derived from
146 cynomolgus blood samples were compared to known human ranges, and it was
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detennined that the CD4/CD8 ratio was reversed from that ofhumans. Further,
preparation from peripheral whole blood using a lysing agent, rather than a density
gradient technique, was advocated as it allowed concurrent evaluation ofhematologic and
clinical biochemistries using only a single, small sample. This article does mention a
gating technique wherein "lymphocytes were gated from other leukocyte types based on
forward and 90 degree light scatter". Lymphocyte subpopulation values as well as
hematologic values were provided in this paper.
In 1995, Verdier et at used two-color (pE and FITC) flow cytometric
irnmunotyping to investigate cross-reactivity of commercially available human reagents
with cynomolgus monkey lymphocytes (14). A number of anti-human mAb clones
including CD2, CD4, CDS, and CD20 were evaluated. In this expanded study from
earlier research (32), lymphocyte subtype values on lysed whole blood of 312 adult
cynomolgus monkeys were obtained. Speculation of discrepancies as well as similarities
in these results compared to other research focused on a possible differences in binding
affinities of the mAb clones used among the studies. Because of the large number of
subjects, and the wide variety of clones tested, a panel of specific MAbs was proposed
for cynomolgus subtyping. Again, as with the Bleavins research, a comparison of these
results to established human ranges revealed a reversed CD4/CD8 ratio. One again, the
gating technique is characterized as "the gate was defined to include cells showing
human lymphocyte parameters for forward and right-angle light scatter; the gate was
regularly checked with both human and monkey samples. A total of 3000 lymphocytes
was recorded for each sample". Further, that "cells with a high fluorescent intensity were
compared with unstained cells in the same sample and with cells from the control blood
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sample and were identified as positive cells for the lymphocyte subset under study. n.u~",
were classified in two groups, namely those which provide clearly identified stain.ed cell
sub-populations comparable to human cells and those which did not allow differen iation
of two populations ofstained and unstained cells. Data were assessed qualitatively but no
statistical analysis was performed". This suggests that the lymphocyte gate was
established based on low scatter properties only, without gate optimization.
Two later studies focused on comparisons between cynomolgus adult and neonatal
values ofCD4 and CD8 lymphocytes. Both of these studies used whole blood sample
preparations and two-color flow irnmunophenotyping. Although Baroncelli, et ai, focused
on neonatal parameters, results for 37 adult cynomolgus monkeys were provided [ll. In
this research, «10,000 lymphocytes, gated from leukocyte types based on forward and 90
degree light scatter, were analyzed for each sample by using a FACScan cytometer
(Becton-Dickinson). This research reported no significant sex differences, however, the
reversed CD4/CD8 ratio from that of humans was once again observed. Tryphonas, et al
evaluated CD4 and CD8, and included CD16 and CD20 values for 12 cynomolgus infants
[
13l. Much more detailed information regarding the actual operation of the FACScan flow
cytometer utilized for this research was provided than in any previous study. This
included basic instrument calibration using CaliBRITE beads as a reference standard. An
AutoComp program was utilized to perform three FACScan adjustments, including
singular event gating, PMT gain, and fluorescent compensation. Finally, a QuickCal kit,
was utilized on a daily basis, allowing channel targeting and subsequent comparisons of
fluorescent intensity measurements. Leukocyte separation was performed using the
FicoU-Hypaque density gradient, and lymphocyte subtyping was established on the basis
27
-
The basis of fluorescent intensity. Although' results were compiled as percentage of the
lymphocyte gate and as absolute counts (x 106 cells/ml) using the leukocyte count, no
specific information regarding establishment or optimization of a lymphocyte gate is
provided. Interestingly, this research revealed a population ofCD8+ CD2-lymphoid
cells not previously reported to be present in adult humans or adult cynomolgus monkeys
[IO}. Appendix B summarizes these studies, as well as the reported lymphocyte subset






Following cross-reactivity trials, a panel of reagent pairs duplicating those listed in
Figure 6 would be used to establish an optimal lymphocyte acquisition gate. Once
established, samples from nine healthy cynomolgus monkeys would be analyzed to
evaluate the distribution ofperipheral blood lymphocyte subpopulations. Population
classifications included T-helper cells, cytotoxic T cells, B cells, and NK cells.
ANIMALS
Nine nonnal adult Cynomolgus monkeys (Macaca fascicularis) housed at Abbott
Laboratories Experimental Animal Facility (Abbott Park, IL), were available for use in
this study. Animals were utilized in accordance with Abbott IACUC animal use
protocols. WhoI.e blood was collected via venipuncture of the femoral vein while oon-
anesthetized animals were restrained in plexiglass restraint chairs. Restraint time was




A total of twenty-six mAbs, defining ten clusters of differentiation (CD markers),
most of which were specific for human leukocytes, were tested to determine cross-
reactivity with cynomolgus leukocytes. These antibodies are listed in Appendix A.
Clones were obtained from Becton-Dickinson lmmunocytometry Systems, San Jose, CA'
Dako Inc; Carpenteria, CA; Biosource International, Camarillo, CA; Coulter
Immunotech, France; Pharmingen Inc., San Diego, CA; and Serotec Ltd., Oxford,
England. All mAbs used were purchased as pre-conjugated probes. The amount of mAb
used was that suggested by the manufacturer, either neat, or at recommended dilutions.
Additional dilutions were also prepared and analyzed.
CELL PREPARATION
Unrefrigerated whole blood samples were prepared within 6 hours of collection.
Direct immunofluorescent staining was performed by combining 100 ul of EDTA anti-
coagulated blood, with the recommended concentrations and dilutions of mAbs, in 12 x
75 mm Falcon tubes. This mixture was incubated on ice in the dark for 30 minutes. Red
cells were then lysed using a commercial lysing agent (FACS Lysing Solution, Becton-
Dickinson) in accordance with the manufacturer's guidelines. 2 ml of (1 X) FACS Lysing
Solution was added to each tube, vortexed at low speeds for 3 seconds, and then
incubated for 10-12 minutes at room temperature, in the dark. Samples were then
centrifuged (1500g/2800 rpm) for 3 minutes at 4 C, and washed twice with 2 ml of cold
~o
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PBS. Cells were suspended with 150 u1 ofPBS/0.5 % formaldehyde. Stained cell
preparations were stored at 4 C, and analyzed within 48 hours. Prior to analysis, samples
were diluted with 750 ul of cold PBS. Preparations were then vortexed and analyzed
directly from the Falcon tubes. Tubes containing unstained cells, and FITC- and PE-
labeled isotype controls were also prepared for each sample.
FLOW CYTOMETRIC ANALYSIS
Samples were analyzed on a FACSCalibur Flow Cytometer E0997 (Becton-
Dickinson) using a IS mW 488 argon-ion laser to excite FIrC or PE probes. Initial
instrument calibration was performed with CaliBRITE standard fluorescent beads
(Becton-Dickinson) using FACSComp version 4.0 software. CELLQuest software was
used for the acquisition of experimental data. Unstained cell samples, and fluorescent-
labeled isotype controls were used optimize fluorescence signals, compensation, and
setting of quadrant markers as previously described. Quadrant markers were set to
exclude less than 2 % of the acquired events. Ungated light- and fluorescent scattergrams
were used to identify cross-reactivity of probes. A number of trial runs were performed,
using both human (as a control) and cynomolgus sample preparations. A series of
dilutional trials were also performed. Following cross-reactivity studies, a minimum of




Automated cell counts and leukocyte differentials were performed on each EDTA-
anticoagulated cynomolgus blood sample using the Abbott CellDyne Hematology Cell
Counter series 3500 (Abbott Laboratories, Abbott Park, IL). Cell size discriminators were
set on parameters optimized for non-human primates. Only samples that contained at






More detailed information regarding the monoclonal antibody clones tested for the
cross-reactivity trials is listed in Appendix A, as previously stated. Anti-monkey CD3
clones were commercially available, and all clones tested exhibited strong cross-
reactivity. All anti-human CD4, CD8, and CD20 clones tested were positive. Only one of
the CD14 clones tested cross-reacted (Pharmingen M5E2), and only very dim- taining
was noted by one of the CD56 clones (Becton Dickinson MY3l). No cross-reactivity wa
observed with any of the CD45 or CDl6 clones evaluated.
Whenever possible, clones were chosen based on previously reported positive
cross-reactivities with cynomolgus or other macaque blood lymphocytes. None of the
CD 16 clones tested for this project showed any reactivity. Non-reactivity of CD16
clones B-E16 (Biosource) and 3G8 (Coulter) represents a discrepancy with findings of
Sopper, et ai, where cross-reactivity of these clones was positive. Rhesus monkeys,
rather than cynomolgus monkeys were used, however, which suggests distinction in




The original goal of creating a lymphocyte panel, which included establishment of
an optimal lymphocyte gate utilizing the CD45/CD14 reagent pair technique, could not
be accomplished, primarily due to non cross-reactivity of the CD45 clones tested.
Funding limitations precluded additional testing of other available CD45 clones. An
alternative gating strategy maintaining NCCLS standards was designed for this project.
Instead ofthe CD45/CD14 reagent pair, this protocol proposed and utilized a
triple-antibody cocktail, containing FITC-labeled CD3 and CD56 in combination with
PE-labeled CD20 to establish and optimize the lymphocyte gate. The rest of the panel,
including fluorescent labels, remained essentially unchanged from that listed in Figure 6.
Because no cross-reacting CD16 was found, only CD3 and CD56 were combined tube 7.
FITC-IgGl and PE-IgGl isotype controls were used. Actual clones selected and utilized
are listed in Appendix B. The same backgating protocol as used for the CD451CD 14 gate
optimization was followed, and a stepwise graphical illustration of the following gating
technique is provided in figures 8a - 8h.
Following standard instrument calibration and optimization, and appropriate
unstained and IgG isotype control configuration as previously described, a prepared
sample containing the triple-reagent probe combination was introduced into the flow
cytometer. Figures 8a and 8b depict the resultant FLl/FL2 and light (FSC/SSC)
scatterplot, respectively.
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Figure 8a. Fluorescent dot-plot of FlTC
CDJ/CD56 and PE-CD20 (ungated)
Figure 8b. Ungated FSC and C of
CDJ/CD56 and CD20
Two regions were then defined. Rl was defined to include PE-CD20 events, and
R2 was defined to include the combined FITC-CD3/CD56 event (Figure 8c). These
events were then displayed on the light scatterplot, which was fonnatted to include only










Figure 8e. Define regioos Rl and R2 00
fluorescent plot which correspond to B
lymphocyte population and T and NK
lymphocyte populations, respectively
Figure 8d. Display Rl and R2 on light scatter
. plot which is gated to di!lplay onl:y these
selected regions (G1 and G2).
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A new region (R3) was. then defined on the light scatterplot to include onI 10
sse events. Following R3 definition, the gates were remo ed displaying all ev nts in th
sample (Figure 8e). The events in R3 were then backgated to the fluore cent plot which
was gated on G3 (Figure 8f).





Figure 8e. A region defined as R3 is
created on R3 are backgated to the
fluorescent plot, and displayed as G3
Figure 8f. Only events contained
within an ungated light scatter plot to
include events that represent the
lymphocyte pOllulation.
Calculations for lymphocyte purity and recovery wer as follow. Percent (%)
Lymphocyte Recovery was calculated by dividing the number of events backgated from
RJ (light scatter, ungated) and displayed in the R1 + R2 region of the fluorescent
scatterplot (gated on R3), by the number of events confined to the R3 region drawn on
the light scatter plot (gated on Rl + R2). % Lymphocyte Purity was calculated by
dividing the number of events backgated from RJ (light scatter, ungated) and displayed in
the R 1 + R2 regions of the fluorescent scatterplot (gated on R3), by the number of event
in the R3 region of the light scatterplot (ungated).
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Gate optimization was performed by defining a new region R4 on the same light
scatterplot, and reformatting the graphs appropriately, so that R4 data replaced R data
















Figure 8g. Create and adjust R4 for
optimization of purity and recovery. The R4
gate appears to exclude some lymphocyte
events.
Figure 8h. Calculations for recovery and
purity utilized data collected from
fluorescent scatterplot gated to display only
events contained witbin R4
Using the above calculations on the data collected, R4 wa adjusted until the
criteria for recovery ( 80%) and purity (>90%) was met, establishing th optimal
lymphocyte gate. Appendix e summarizes hematologic value, quantifkation and
percentages of events collected for these regions as described above, and re 'ults of the
recovery and purity calculations. This data was collected on three samples run for each
of9 cynomolgus monkeys. With the exception of the 79.33% lymphocyte purity of the
second sample run for monkey e094, the. eeLS criteria was met in every case.
Following its definition, all other samples from the panel were evaluated through this
gate, and results were collected from each of four quadrants of a FL1/FL2 dot plot. Thes
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results are provided in Appendi es D-G. Av ra e of these result ar list din Appendi
B, which also lists results obtained from other previously r .ewed literatur .
EVALUATION OF GRAPIDCAL D TA
For this study, in order to meet the minimal criteria of purity and recovery,
definition ofthe R4 gate resulted in an area that becomes closely confluent with th
uppermost portion of the lymphocyte cloud. The shape of the R4 gate was consistent
throughout aU monkeys and all samples assessed. The gate structure appear to elude
some events, presumed to be lymphocytes, in order to maintain quality control. In order
to further evaluate what, if any, lymphoid events may have been excluded secondary to
the defined gate perimeter; several regions were defined and assessed for one of the
FITC-CD3/CD56 PE-CD20 samples (Figure 9a - 9d). Three regions were defined to
include three distinct event clouds, on an ungated fluorescent dot-plot as depicted in










Figure 9a. User defined regions and colors
are defined on fluorescent dot plot.
Figure 9b. All events of fluorescent plot
are displayed on ungated light scatterplot.
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These populations were assigned user-defined colors and were further a sessed on
an ungated light scatter plot for evaluation of physical properties ofcellular size and
complexity. These defined regions isolated what appear to be four di tinct c IL
populations. Based on fluorescent properties these regions were pre umed to repre ent
cell populations as follows: RI (orange)=B cells; R2 (green)=B cells' R3 (red)=AlI T and
NK cells; U (blue)=unstained, negative population. The upper right quadrant al 0
contains what is presumed to be nonlymphoid (undesired events). The ungated light
scatterplot (Figure 9b) reveals a black (negative events) cell population at the uppermost
aspect of the lymphocyte cloud. This suggests that many of these events are
nonlymphoid, however, distinct resolution is
not possible due to summation.
These cell populations were then
assessed via a FLIIFSC scatter pot (Figure 9c).
The combined use of fluorescence of FITC-
CD3/CD56+ events and cellular size and
complexity would allow isolation of small
events displaying fluorescence, specifically the T and
NK lymphocyte population. A cloud ofFITC-
CD3/CD56+ events (red cloud) with low FSC
Figure 9c. FlTC CD3/CD56 llnd FSC
dot plot. The red cloud corrc!lponds
with T and NK lymphocyte
populations.
properties is revealed in figure 9c, which corresponds to the events contained with region
R3 (Figure 9a). This cloud should represent all T and NK-cells, however, it is not
completely delineated. There appears to be a small amount of continuous staining of
green and black events, suggesting some B cell and nonlymphoid event fluorescent
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overlap. Further, a small population of higher FSC black events also exhibits some FfT
fluorescence, again suggesting some fluorescent overlap with the negative c II
population. Additionally, another FL2IFSC graph was creat d to display PE-CD20+
fluorescence, which should represent all B lymphocytes (Figure 9d). Asses ment of this
plot reveals a green cloud that exhibits
low FSC and high PE fluorescent intensity,
corresponding to presumed B cells of R2. A
smaller, apparently black cloud overlaps this
population, again suggesting some
fluorescent overlap with the presumed
negative population. Previously described
techniques limiting background fluorescence
o 200 400 600 800 1000
FSC-Helght
were performed prior to this analysis, which
should have limited this overlap. Whether this
Figure 9d. FITC CD3/CD20 and FSC
dot plot. The green cloud corresponds
with B Iymphoc te Impulation
overlap represents limitations in flow cytometric instrumentation, or operator error In
instrument optimization and control settings cannot be definitively determined. Thi
overlap ofapparent nonlymphoid events, however, appears to justify the final contours of
the R4 lymphocyte gate.
Also present on figure 9d is a distinct orange cloud of events, which displays a
lower level of PE fluorescent intensity, and greater FSC properties than the B cell
population. These cells may represent a larger, possibly reactive B-cell population,
another distinct lymphoid population that also expresses CD20, or overlap with a
nonlymphoid population, possibly monocytes, that exhibit weak PE fluorescence. Some
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of this cloud was omitted by the confines ofthe original Rl gate (figure 9a). Whether
these events should have been included in the final subtyping analysis remains
undetermined.
Finally, the protocol used on the current study utilized the IgG isotype controls
prior to establishing the lymphocyte gate. General guidelines and some previous research
suggested this sequence of isotype control usage for lymphocyte subtyping. It is possible,
however, that had the isotype controls been run following establishment of the
lymphocyte gate, and confined within the R3 or R4 region (s), a larger amount ofnon-
lymphoid events may have been excluded, More research is needed for clarification.
EVALUATION OF NUMERICAL DATA
Results from this study were comparable to reported findings of previously
reviewed literature, Appendix B provides a summary of these results. No other research
evaluated an anti-monkey CD3 as a pan-T cell mark~r, using instead an anti-human CD2
marker. This may reflect the unavailability of monkey-specific reagents at the time of this
previous research, Rounded, averaged results for CD2 ranged from 56% - 76%, with a
mode of 56%, and a mean of 65%, Averaged CD3 results for this study were 61 % The
range for CD4 was 28% - 53%, with a mode of40% and a mean of 31. 5%. Averaged
CD4 results for this study were 29%, The range for CD8 was 25% - 480/0, with a mode of
25% and a mean of33%, Averaged CD4 results for this study were 33%, The range for
CD20 was 12% - 25%, with a mean of 19%, Averaged CD20 results for this study were
22%, No CD56 results were provided in any of the research reviewed. Averaged results
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of CD56 for this study were 4.80%. It appears that all results generated from this study
were within the limits of previously reported research. Overall, the data from this
research most closely resembles that reported by Verdier, et al., where averaged results
for 312 male and female cynomolgus monkey CD2, CD4 and CD8 results were 56.5%,
29.5%, and 37%, respectively. The procedure used in this study was similar to that used
by Verdier, with the exception that different clones were used, and no CD20 or CD56





Although only a limited number of studies specifically aimed at subtyping
peripheral blood lymphocyte subpopulations in cynomolgus monkeys using flow
cytometric immunophenotyping was available, results of this current study were well
within the averaged values reported by this research. Discrepancies in actual numerical
values among all studies may be attributed to variations in sample preparation, binding
affinities of clones used, and/or gating techniques utilized. As previously stated, the
general shape of the lymphocyte gate that resulted when lymphocyte recovery and purity
was optimized during this project requires further investigation. What lymphocyte
population, if any, and percentage thereof may have heen excluded by the gate, remains
undetermined. Assuming the general gate shape persists if this protocol is utilized, future
studies may incorporate a more detailed evaluation of this gate phenomenon.
Although clone panels have been suggested (Verdier, et al), no specific gating
technique has been described or submitted as part ofany protocol. It is clear that a
reproducible protocol, wruch includes lymphocyte gating optimization in accordance with
NCCLS guidelines, is needed. This current study submits a complete protocol, which
includes a panel of cross-reacting clones, and thoroughly describes a gating procedure,
which, to the best of this author's knowledge, has not been previously described.
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Additionally, further studies are needed to prove reproducibility of this proposed
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APPENDIX A.
Commercial monoclonal antibodies tested for cross reactivity.
Soun:e Ant1botly Clone Label botype Host Amount Rndh1ty CataloC#
(tOOlI per •
test)
Serotee CD3 FNI8 FITC IgGI mouse S mIISO ul Positive MCAI483F ••
(anti-
monkey)
CD8 LT8 PE IgGl mouse I mIIIO u1 N~futed MCAI226P
CD8 YTC FITC IgGI rat I mill 0 ul N~ lilted MCAlSIF
182.20
CDI6 LNKI6 PE Igl 2b mouse I mIIlO ul N~lilted MCA1l93P
CDlO B-HZO PE Ill! I mouse I mIIlO ul N~ listed MCA9S3P ••
CDS6 B-A19 PE Ill! I mouse I mIIlO ul N~ listed MCA670P
BI08O~r CD3 FNI8 FITC IgGI mouse 1 mIII0 ul Positive APS0308
(anti-
monkey)
CD4 EDU-2 PE IgG2a mouse I mIIlO ul N~ listed AHS0417
CDI6 B-E16 PE 19O1 mouse I mIIlO ul Positive AHSI607
1
DAKO CD4 MT310 PE IgGl mouse I mIIlO ul Positive R080S ..
CD8 DlaS PE Ill: I mouse I mIIlO u1 Positive R0806 ••
CD20 B-Lvl PE Ill: I mouse 1 mIII0 ul Positive R7013
CDS6 MOCI PE I~ 1 mouse 1 mIII0 u1 Positive R7127
Coulter CD8 8911 PE 19O1 mouse 2m1120 ul Positive [M04~2
CDI6 3G8 PE 1l!:GI mouse 2 m1120ul Positive [M1238
CD20 89E9 PE htG2a mouse 2 m1120 ul N~listed [M14~1
Becton- CD4 SIG PE IgGl mouse 2 ml/20 ul Positive 347327
Dtcldnson
CDI4 MOP9 PE Ill; :2b mouse :2 ml/:20 ul N~lillted 347497
CDI6 NKPI5 FITC Ig 1 mouse :2ml/20 ul N~ listed 347627
CD4~ L:243 FITC Ig 20 mouse 2 mV20ul N~ listed 347427
CD56 MY31 PE 19o I mouse :2 mV20 ul Negative 347747 ..
CDS6 Leu-I 9 PE IgGl mouse :2 mV:20 ul N~lilll.ed 347697
Pharmtngen CDI4 MSE2 PE 19G2a mouse :2 m1J:20 ul N~ listed 30~4~X
C020 :2H7 PE lll::2bl mouse :2 m1J:20ul N~ Iist.ed 3326~X
CO2 I B-Ly4 PE IgGl mouse :2 mV20ul N~ listed 3069SX
Serotec [l!:G I FITC mouse lOOT MCA928F ••
(isotype [l!:GI PE mouse lOOT MCA928P ••
controls) IgG2a PE mouse lOOT MCA929P
htG2b FlTC rat lOOT MCA112SF
*Cross-reactivity of human clone with cynomolgus monkeys if known.
**Final pane] of antibodies and isotype controls selected for this research
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APPENDIXB.
Summary of results from literature and the current study.
Author # of subjects Antigens Antibody Label Results (%)
in sample Targeted clones Male Pooled Female
Levtin 7 CD2 TI2 FITC 56 +/- 9
(1983) CD4 T4 mc 33 +/- 16
CD8 T8 mc 25 +/- 11
Sagara 30f T cells Til FITC 72.1 +/- 2.4
(1990) B cells Anti-monkey FITC 24.6 +/- 2.4
Bleavins 69m CD4 Anti-leu 3a PE 28 30
(1993) 77f CD8 Anti-leu 2a PE 56 54
CD20 Anti-leu 16 PE 12
Verdier 153m CD2 Anti-leu 16 mc 56 +/- 18 57+/-17
(1995) 159f CD4 OKT4 mc 30 +/- 11 29 +/- 11
CD8 Anti-leu 2a PE 37 +/- 14 37 +/- 14
CD20 Anti-leu 16 FITC no results listed
Tryphonas 6m CD2 Ortho mc *75.57 +/- 4.85 77.5+/- 4.85
(1996) 6f CD2 BD mc
CD4 Ortho FITC *40.07 +/- 8.18 53.3+/- 3.72
CD4 BD PE
CD8 Ortho FITC *48.57 +/- 9.06 38.61+/- 3.34
CD8 BD PE
CD16 Ortho FITC no results listed
CD16 BD PE
CD20 BD PE 23.14+/-3.21 19.96+/- 3.60
*Results were pooled when
multiple clones for individual
antigens were used.
Barooecelli 17m CD4 DAKOMT31O PE 40.5
(1997) 20f CD8 DAKODK25 FITC 25.5
Decker 6m CD3 Biosource FN18 FITC 60.79**
(1998) 3f CD4 DAKOMT310 PE 28.75
CD8 DAKODK25 PE 33.50
CD20 Serotec B H2O PE 22.40
CD56 BDMY31 PE 4.80
m=maJe, f=female
** Results were averaged from CD3/CD20 and CD3/CD56 samples only.
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APPENDIXC
Hematologic values and results of calculations for lymphocyte recovery
TWBCC LVM %LVM SC Il4 SC R3 ilL III +Itl CDlI211156 %t'UlUTV %
MOt'''F.\· NO GATE NOCATE ilL RECOVER
D3/211156 CDJIlOl5' C3(R1+IU) FU'J[RI+1
tc3<RJI F~Ull+1
.':-t.j~,r··.' G~ G-R4 G-tu C-RJ
£VENT %GT EVIINT %GT
(RI+IU) (Rl+Rl)
EVE % GAT EVE %<lAT ,.. -
C0537~ 13.7 8.39 61.2 6j9j 63.93 510~ 51.04 4525 7U.78 40'/01 NO~I 80.21 90.4
C0537n9 RI 6663 66.63 5493 ~.93 SOOI 75.05 4311 12.13 82.13 90.2
C05J?n9 R1 6893 63.93 5999 59.99 5185 75.23 4829 80.50 80.50 93.1
C0577/28 16.2 11.7 72.3 7784 77.84 69.55 69.55 6374 81.&3 6088 87.53 87.53 95.5
OIS77/291l1 7798 77.98 7145 71.45 6351 II.U 6106 J'.4) RH) 96.1
C0577/29 R1 7498 74.98 6597 65.97 6101 81.37 5627 ISJ 85.3 92.2
COGI 7/28 12.5 8.54 68.3 75U6 75.06 6190 61-'!O 6030 80J4 5520 8918 M.18 9U
CO"?n9 RI 7488 74.18 601 M.81 5606 74.84 5200 80.23 8U.23 92.8
C061 7m R1 74~~ 7'.9~ 6525 M.25 5657 75.49 5317 11.49 81049 94.0
COU 7/28 17.2 11.0 64.0 62101 6214 5~UU 54.0 5290 85.13 4812 89.3 89.3 91.2
C042 7/29 RI 6112 61.22 5587 55.87 J915 1028 4655 &3.32 83 12 94.1
C042 7129 R2
-
(,)31 63.31 5819 58.89 5166 11.60 4981 84.58 XU8 1J().4
0047/28 13.7 4.87 51.0 5467 ~.I17 4229 4U9 3969 72.60 3660 86.>4 86.54 92.2
C0747129 III 565S 56.55 4_ 46.06 3971 70.ll 3660 79.46 79.46 92.2
C074 7129 R1 S684 56.84 4476 44.7(, 3973 69.90 3602 80.47 80.47 907
C094711J1 11.1 ~.22 47.1 4948 4941 .<1:!'9(, 42.96 3706 74.9 35U4 81.56 IU6 94.5
C0941129 RI 4672 46.72 35HO 35.80 1344 71.57 2140 79.33 70.33 1\0192
(;0947/29 R2 486J 41.61 oI02~ 40.25 3582 7169 J2J2 80.3 80.1 ~0.2
A~U57121 12.1 2.43 20.0 209·1 20.94 II" IUS lM47 8&20 1(,74 91.23 91.23 I)U.b
MOS7129 RI 2161 2161 U82 11.82 1779 8233 1616 8Ub 90.8
A405712'JR1 Zill 21.51 U97 18.97 817 84.65 16~0 86.98 '11).8
A4537/28 6.08 2.37 39.0 )948 39.41 36U6 J6.06 161J 93.23 347R 96.45 %.45 94.5
A453 7/29 RI 329U 32.90 2779 27.79 2602 79.06 23~1 ~.60 84.60 90.4
,\4537129 R2 l1J9 32.39 1928 1911 2(04S 11.66 2~9J AS.II ASH 94
n0657128 11.2 3.42 30.5 3101 31.01 2760 27 hO 2('s9 8S.71 H59 A9.09 89.09 97.'
D0657f191l! 4070 4U.7U 3738 37.38 3751 92.1(, 3S15 9411 ·)40 9-4.1
n06S 7/2') R2 4210 42.10 181 I J831 3H26 90118 30U8 94.2 94.2
IR~171/29 185 12.5 67.9 545J 54.53 48) I 4831 448(, 12.27 4141 85.72 1l.72 92.3
2RC0427f1.' 5533 SS 3J 4H(,(, 4866 4J21 78.22 392J 80.6l 811 hl 90.6
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APPENDIXD
Summary of Data for CD3/CD4. All final runs and monkeys tested.
CD3/CD4 G3 UL UR LL LR
MONKEY TOTAL CD3-CD4+ CD3+/CD4+ UNSTAINED CD3+EVENTS
EVNT % EVNT % EVNT e;. EVNT %
COS37f28 4717 62 1.31 1097 23.26 2223 47.23 1330 28.20
COS3 7f2IJ RI 4730 367 7.76 115 I 24.33 2038 43.09 1174 24.82
C0537f29 R2 5596 631 11.28 1352 24.16 2322 41.49 1291 23.07
C0577f28 6668 111 1.62 2309 33.62 2469 35.95 1979 28.81
COS7 7f29 RI 7115 98 1.38 2240 31.48 2888 40.59 1889 26.55
COS7 7t29 R2 6567 48 0.73 2206 33.59 2441 37.17 1872 28.51
COG17/28 6018 57 0,95 1740 28.91 2196 36.49 2025 33.65
C0617129 RI 6277 30 0.48 1742 27.75 2493 39.72 2012 32.05
COM 7129 RZ 6170 23 0.37 1678 26.76 2390 38.12 1179 34.75
C0427/28 ' 5731 33 0.58 2143 37.39 1866 32.56 1689 29.47
C042 7/29 RI 5720 25 0.44 1980 34.61 2012 35.17 1703 29.77
C0427129R2 6075 40 0.66 2150 35.39 2160 35.56 1725 28.40
C0747128 4321 30 0.69 1279 29.60 1965 45.48 1047 24.23
C074 7129 RI 4518 21 0.46 1227 27.16 2250 49.80 1020 22.58
C074 7/29 R2 4319 25 0.58 1220 28.15 2026 46.91 1048 24.26
C0947t28 4193 38 0.91 1713 40.85 1488 35.49 954 22.75
C094 7129 Rl 3646 6 0.16 1505 41.28 1236 33.90 899 24.66
C094 7/29 R2 4158 17 0.41 1657 39.85 1565 37.64 919 22.10
.404057128 2096 24 1.15 756 36.07 639 30.49 677 I 32.20
.404057129 Rl 2280 23 1.0 I 736 ' 32.28 801 35.13 720 31.58
.404057/29 R2 2158 27 1.25 745 34.52 686 31.79 700 32.44
.404537/28 3428 27 0.79 1349 39.35 984 28.70 1068 31.\6
.404S3 7129 RI 2826 II 0.39 702 24.84 799 28.27 1314 46.50
.404S37129R2 2800 15 0.54 716 25.57 821 29.32 1248 44.57
80657128 2715 20 0.74 767 , 28,25 778 28.66 1150 42.36
B065 7129 RI 3870 45 1.16 1363 35.22 1294 33.44 1168 30.18
n065 7t29 R2 3726 37 0.99 1384 3714 1142 30.65 1163 31.21
IRC0427/29 4614 56 1.21 1232 26.70 1869 40.51 1457 31.58
2RC0427D.9 4449 64 1.44 1174 26.39 1921 43.18 1290 29.00
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APPENDIXE
Summary ofData for CD3/CD8. All final runs and monkeys tested.
CD3/CD8 GJ UL UR LL LR
MONKEY TOTAL CD3-CD8+ CD3+/CD8+ UNSTAINED COli-
EVENTS
EVNT .'" EVNT % EVNT % EVNT %
COS37/28 4463 1274 28.55 1361 30.50 1034 23.17 1034 17.79
COS37129 RI 4648 1496 32.19 1422 30.59 1013 21.79 717 15.43
COS3 7/29 R2 519! 1687 32.50 1504 28.97 1336 25.74 664 12.79
COS77/28 6927 1239 17.89 2389 34.49 1351 19.50 1948 28.12
COS77129 Rl 6972 1370 \9.65 2295 32.92 1400 20.08 1907 27.35
COS7 7/29 R2 6564 1317 20.06 2342 35.68 981 14.95 1924 29.31
C0617/28 6210 1246 20.06 241l 38.82 lOll 16.28 1542 24.83
C061 7/29 RI 6567 1418 21.59 2414 36.76 1106 16.84 1629 24.81
C061 7/29 R2 6609 1422 21.52 2361 35.72 1162 17.58 1664 25.18
C0427/28 5458 580 10.63 1809 33.14 1146 21.00 1923 35.23
C0427/29 Rl 5607 650 L\.59 1690 30.14 1323 23.6 1944 34.67
C042 7/29 R2 5830 591 10.14 1730 29.67 1529 26.23 1980 33.96
C0747/28 4481 574 12.81 1132 25.26 1545 34.48 1230 27.45
C074 7/29 Rt 4767 462 9.69 2341 49.11 367 7.70 1597 33.50
4767 (787) (16.5\) (1049) (22.01 ) (1323) (27.75)
C074 7f29 IU 4541 396 8.72 2276 50.12 341 7.51 1528 33.65
4541 (701 ) (I5.44) (1020) (22.46) (1292) (28.45)
C0947128 4218 835 \9.80 892 21.15 775 18.37 1716 40.68
C094 7/29 Rl 3598 647 \7.98 774 21.51 655 18.20 \522 42.30
C094 7129 R2 4067 802 19.72 942 23.16 755 18.56 1568 38.55
A4rr57128 1958 1\9 6.08 754 38.5\ 442 22.57 643 32.84
A40S 7/29 RI 2435 1\9 4.89 722 29.65 949 38.97 645 26.49
A405 7129 R2 2344 121 5.16 781 33.32 764 32.59 678 28.92
A4537/28 3332 247 7.41 958 28.78 759 22.78 1368 41.06
MS] 7/29 RI 2681 364 13.58 1235 46.06 433 16.15 649 24.2J
A4S] 7f29 R2 2733 265 9.70 1217 44.53 5&7 21.48 664 24.30
I 80657128 2661 308 11.57 1134 42.62 509 19.\3 710 26.68
80657/29 RI 402S 248 6.16 1027 25.52 1385 34.41 1365 33.91
80657129 R2 3727 272 7.30 L059 28.41 976 26.19 1420 38.1()
1RC042 7/29 4622 672 14.54 1706 36.91 1239 26.81 1005 I 21.74
2RC0427/29 4504 738 1639 \512 33.57 1323 29.37 931 20.67
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APPENDIXF
Summary ofData for CD3/CD20. All final runs and monkeys tested.
CD3/CD20 G3 UL 'UR LL LR
MONKEY
TOTAL CD3-CD20+ CD3+/CD2O+ UNSTAINED CD3+
EVENTS
EVNT ~. EVNT ~. EVNT % EVNT 0/0
i
COS37/28 4568 1335 29.23 133 2.91 1081 23.66 2019 44.20
COS3 7n9 Rl 4865 1419 29.17 353 7.26 1258 25.86 1835 37.72
C0537/29 R2 5218 1622 31.08 332 6.36 1379 26.43 1885 36.12
COS77/28 6894 1863 27.02 210 3.05 769 1U5 4052 58.78
C0577/29 R1 7133 1673 23.45 255 3.57 1151 1.6.14 4054 56.83
COS7 7/29 R2 6517 1425 21.87 232 3.56 984 15.l0 3876 59.48
C0617/28 6096 1409 23.11 183 3.00 802 13.16 3702 60.73
C061 7n9 Rl 63.50 1231 19.39 151 2.38 1250 19.69 3718 58..5.5
C061 7/29 R2 6551 1368 20.88 170 2.60 1242 18.96 3771 57.56
C0427/28 5710 1298 22.73 244 4.27 644 11.28 3524 61.72
C042 7/29 RI 5505 1192 21.65 220 4.00 838 15.22 3255 59.13
C042 7/29 R2 5685 1358 23.89 196 3.45 705 12.40 3426 60.29
C0747128 4312 1442 33.44- 140 3.25 630 14.61 2100 48.70
C0747129 RI 4559 1323 29.02 (27 2.79 1051 23.05 2058 45.14
C074 7129 R2 4200 1282 30.52 123 2.93 676 16.10 2119 50.45
C0947/28 4446 1020 22.94 96 2.16 672 15.11 2658 59.78
C094 7/29 R1 3807 782 20.54 27 ! 0.71 637 16.73 2361 62.02
C0947/29 R2 , 4121 876 21.26 43 1.04 700 16.99 2502 60.71
A40S 7/28 1967 412 20.95 75 3.81 158 8.03 1322 67.21
A4057/29 Rt 2544 327 12.85 9 0.35 696 27.36 1512 59.43
A40S 7/29 R2 2428 350 14.42 3 0.12 551 22.69 1524 62.77
A4537/28 3423 844 24.66 119 3.48 189 5.52 2271 66.35
A453 7/29 RI 2808 368 13.11 27 0.96 505 17.98 1908 67.95
A4S3 7/29 R2 2849 377 13.23 25 0.88 487 17.09 1960 68.80
!
B065712S 2855 456 15.97 89 3.12 388 13.59 1922 67.32
B065 7/29 Rt 4496 842 18.73 30 0.67 1185 29.36 2439 54.25
80657/29 R2 3882 805 2D.7-l 19 0.49 499 12.85 2559 65.92
LRC0427/29 4501 1229 27.31 419 9.31 650 14.44 2203 48.94
2RC0427/29 4346 1286 29.59 408 9.39 662 15.23 1990 45.79
54
APPENDIXG
Summary of Data for CD3/CD56. All final runs and monkeys tested.
CD3/CD56 G3 UL UR LL LR
MONKEY TOTAL CD3-CD56+ CD3+/CDS6+ UNSTAINED CD3+
EVENTS
EVNT % EVNT . ~. EVNT % EVNT ~.
COS37/28 4595 240 5.22 2LO 4.57 2060 44.83 2085 45.83
COS3 7/29 Rl 4835 570 11.79 689 14.25 1831 37.87 1745 36.09
COS3 7/29 R2 5563 794 14.27 874 15.71 2023 36.37 1872 33.65
5563 () () () () () ( ) () ()
COS7712fJ 6920 L 0.01 160 2.31 2376 34.34 4383 63.34
COS7 7r29 Rl 7193 25 0.J5 933 12.97 2449 34.05 3786 52.63
(4432) (61.62)
COS7 7f29 R2 6707 15 0.22 845 12.60 2124 31.67 3723 55.51
(4341 ) (64.72)
CG617f28 6180 421 6.8J 267 432 1805 29.21 3687 59.66
C06l 7129 Rl 6588 272 4.13 83 1.26 2331 35.38 39G2 59.23
C0617/29 R2 6630 339 5.11 89 1.34 2214 33.39 3988 60.15
CO..27128 5593 279 5.02 282 5.07 1557 27.99 3445 61.93
con 7f29 RI 5482 199 3.63 89 1.62 1838 33.53 3356 61.22
C042 7f29 R2 5617 304 5.41 III 1.98 1800 32.05 33402 60.57
C0747f28 4231 Jl8 2.79 127 3.00 1820 43.02 2166 51.19
C074 7f29 Rl 4512 130 2.88 167 3.70 2186 48.45 2029 44.97
C074 7129 R2 4182 108 2.58 162 3.87 1876 44.86 2036 48.68
C0947128 4361 94 2.16 127 2.91 \447 33.18 2693 61.75
C094 7129 RI 3464 30 0.87 168 4.85 1043 30.\\ 2223 64.\7
C094 7/29 R2 4121 876 21.26 43 1.04 700 \6.99 2502 60.71
A40S 7/28 1937 178 9.l9 113 5.83 363 18.74 \283 66.24
A4057129 RI 2033 193 9.49 37 1.82 538 26.46 1265 62.22
A40S7129 R2 2048 202 9.86 42 2.05 460 22.46 1344 65.62
A4SJ 7128 3299 180 5.46 81 2.46 646 19.58 2392 72.51
A4S37129 RI 2661 75 2.82 26 0.98 707 2657 1853 69.64
,\4537129 R2 2865 147 5.13 23 0.80 770 26.88 1925 67.19
B0657128 2739 12& 4.67 J14 416 665 24.28 1832 66.89
B065 7/29 RI 4223 185 4.3& 190 4.50 1276 30.22 2572 60.90
B065 7/29 R2 3993 215 5.38 178 4.46 1103 27.62 2497 62.53
1RC042 7fl9 4337 378 8.72 348 8.02 1434 3306 2177 50.20
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